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Abstract
Background: The triad of digital rectal examination (DRE), serum prostate specific antigen, and transrectal 
ultrasound-guided prostate biopsy is used in the detection of prostate cancer (PCa). It is recommended that all cases 
of PCa should be diagnosed with needle biopsy before treatment. The exclusion criteria for those that may not be 
suitable have not yet been defined.
Materials and Methods: We reviewed all the patients diagnosed with PCa at the Nnamdi Azikiwe University Teaching 
Hospital Nnewi, Southeast, Nigeria, from January 2007 to December 2010. Relevant biodata and method of diagnosis 
of PCa before treatment were reviewed.
Results: A total of 133 patients had bilateral orchidectomy over the period. 120 (90.2%) had their diagnosis confirmed 
by needle biopsy before bilateral orchidectomy (category 1), while 13 (9.8%) had bilateral orchidectomy before diagnosis 
was confirmed. The method of diagnosis for category 1 patients was with lower urinary tract symptoms (LUTS), abnormal 
DRE findings, elevated prostate-specific antigen (PSA), and transrectal needle biopsy. For category 11 patients, diagnosis 
of PCa was suspected based on LUTS, abnormal DRE findings, and elevated PSA. Of this number, 11 (84.6%) had, in 
addition, sudden onset paraplegia at presentation, while 2 (15.4%) had severe uncontrolled hematuria at presentation. 
All the patients in both categories had needle biopsy confirmation of their disease. The sensitivity of PSA was 99.2%.
Conclusion: Needle biopsy of the prostate is the preferred method for the diagnosis of PCa in most cases before 
treatment is undertaken. There are valid reasons why all PCas will not be diagnosed in this fashion. Elevated PSA 
when combined with an abnormal DRE finding increases the predictive value for cancer. In areas where pathologists 
are lacking, abnormal DRE and elevated PSA results can be a guide to proceed to treatment especially, where there is 
severe compromise of patients’ quality of life due to symptoms of advanced PCa while awaiting confirmation.
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Introduction
Prostate cancer (PCa) is the most commonly diagnosed 
malignancy and the second most common cause of cancer 
deaths among men.[1] In countries where prostate‑specific 
antigen (PSA) screening has been adopted, the number of 
new cases of PCa diagnosed has increased dramatically.[2] 
In developing countries like Nigeria, where widespread use 
of PSA for screening is not routine, most patients present 
with late disease and as such, the most common form of 
treatment is primary androgen ablation.[3‑5]
General recommendation for diagnosis of PCa before 
treatment involves a digital rectal examination (DRE), 
PSA testing, and biopsy either transrectal ultrasound 
(TRUS) guided biopsy[6] or digitally guided biopsy. 
Needle biopsy allows appropriate surgical treatment for 
patients whose biopsy specimen is benign, allows better 
treatment planning, and also helps in grading of the 
tumor.[7,8]
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In our centre, we have always preferred diagnosis by needle 
biopsy whenever feasible. In this report, we review all PCas 
diagnosed in our centre, to determine the percentage of 
cases that were diagnosed by needle biopsy or not and why?
Materials and Methods
We reviewed the case notes of patients who were diagnosed 
with PCa at the Nnamdi Azikiwe University Teaching 
Hospital, Nnewi, Southeast, Nigeria, from January 2007 to 
December 2010. Relevant biodata and method of diagnosis 
of PCa before treatment were reviewed. Patients were then 
categorized into two groups based on whether a diagnosis 
was made before treatment or after treatment. Sensitivity 
of PSA was calculated using the formula TP/TP+FN 
(TP ‑ true positive and FN ‑ false negative). Results were 
analyzed using Microsoft Office Excel® 2007.
Results
A total of 133 patients had bilateral orchidectomy over the 
period. The mean age of the patients was 70.0 ± 10.1 years, 
range 50–96 years. Most patients were in the seventh and 
eight decades of life. Of this number, 120 (90.2%) had 
their diagnosis confirmed by needle biopsy before bilateral 
orchidectomy (category 1), while 13 (9.8%) had transrectal 
biopsy for diagnosis at the time of bilateral orchidectomy 
(category 11).
The method of diagnosis for category 1 patients was with 
lower urinary tract symptoms (LUTS), abnormal DRE 
findings, elevated PSA, and transrectal needle biopsy. 
For category 11 patients, diagnosis of PCa was suspected 
based on LUTS, abnormal DRE findings, and elevated 
PSA. Of this number, 11 (84.6%) had in addition, sudden 
onset paraplegia at presentation, while 2 (15.4%) had 
severe uncontrolled hematuria at presentation [Table 1]. 
All the patients in both categories had needle biopsy 
confirmation of their disease. The reason for not having a 
needle biopsy confirmation before therapy was mainly that 
of the surgeon. The average duration of presentation for 
patients with sudden onset paraplegia was 7.0 ± 3.8 days, 
range 2–14 days. The average follow‑up period for 
patients with paraplegia was 15.3 ± 6.4 months, range 
6–24 months. Nine (81.8%) of the paraplegic patients 
regained the use of their limbs at a mean follow‑up period 
of 48.7 ± 27.6 days, range 21–96 days. The requirement 
for blood transfusion was also significantly reduced after 
bilateral orchidectomy in patients with severe uncontrolled 
hematuria. All the patients in this study had an abnormal 
DRE on clinical examination (sensitivity of 100%). Only 
1 (0.8%) had PSA levels less than 4 ng/ml [Table 2]. All 
the patients with paraplegia and severe hematuria had 
markedly elevated PSA. The sensitivity of PSA in this 
study was 99.2%.
Discussion
The triad of DRE, serum PSA, and TRUS‑directed prostate 
biopsy is used in the detection of PCa. DRE and serum 
PSA are the most useful first‑line tests for assessing the risk 
of PCa.[9,10] In our centre, routine evaluation for patients 
presenting with LUTS due to PCa, usually involves a medical 
history, clinical examination including a DRE, laboratory 
and radiological assessments including a PSA. PSA increases 
the predictive value of DRE for cancer.[9,11] However, PSA 
can also be elevated in other diseases of the prostate or 
following prostate manipulation (prostatic massage and 
prostate biopsy).[12] Therefore, any patient with a suspicious 
DRE and an elevated PSA should undergo prostate biopsy.
Prostate biopsy can be performed under digital or TRUS 
guidance. TRUS provides an excellent visualization of 
the prostate.[13] This and the ability to direct the biopsy 
needle precisely into regions of interest clearly gives it 
more advantage to digitally guided biopsies which are 
blind.[13] Weaver et al.[14] in comparing the cancer yield 
from digitally and ultrasound guided prostate biopsy in 
51 men with palpable prostate abnormality, noted carcinoma 
in nine of the patients with digitally directed biopsy. In 
contrast, 23 men had carcinomas detected when biopsy was 
performed under ultrasound guidance. Each of the men, who 
had positive digitally guided biopsy results, had carcinoma 
also detected on ultrasound‑guided procedure. Lippman 
et al.[15] observed carcinoma on TRUS biopsy in 9% of men 
with negative digitally guided biopsy results. All the patients 
in this study had digitally guided prostate biopsy.
Table 1: Method of diagnosis of prostate cancer before 
treatment
Method No of 
patients
Percentage 
LUTS/abnormal DRE/Elevated PSA 120 90.2
Needle biopsy
LUTS/paraplegia/Abnormal DRE/Elevated PSA 118.3
LUTS/severe hematuria/Abnormal DRE 2 1.5
Elevated PSA
Total 133 100
PSA = Prostate specific antigen, DRE = Digital rectal examination
Table 2: Predictive value of abnormal DRE and PSA in 
the diagnosis of PCa
Method of diagnosis PSA (ng/ml)
<4 n (%) 4–100 n (%) >100 n (%)
Diagnosis before treatment 1 (0.8) 115 (95.8) 4 (3.3)
Diagnosis confirmed after 
treatment
With paraplegia ‑ 4 (36.4) 7 (63.6)
With hematuria 2 (100) ‑
PSA = Prostate specific antigen, DRE = Digital rectal examination,  
PCa = Prostate cancer
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There are clearly many advantages of needle biopsy. For 
those whose biopsy specimens are benign, appropriate 
early treatment can be applied. For those with cancer, 
preoperative diagnosis allows better treatment planning 
and improved patient education regarding the alternative 
treatment options.[16]
In patients with PCa, surgical castration or the use of other 
methods that lead to a decrease of testicular androgen 
production and of plasma testosterone levels usually results 
in a favorable response.[17] This form of therapy is commonly 
applied to either locally advanced or metastatic PCa.[18] This 
explains the reason for the control of symptoms of PCa in 
patients with metastatic disease after surgical castration. In 
our environment, the absence of routine screening with PSA 
to detect early cases of PCa implies that most of our patients 
present late, therefore, the commonest mode of therapy 
in most cases is surgical castration. The data presented in 
this report suggest a few situations in which diagnosis with 
needle biopsy may not be necessary before treatment. This 
decision may become necessary in centres where PSA results 
as well as biopsy results take long period of time to be issued 
or places where trained pathologists are lacking. It also seems 
plausible that timely hormone ablation appears to reverse 
progression of paraplegia to an irreversible state. Also early 
hormone ablation appears to control severe bleeding from 
PCa and so reduce the requirements for blood transfusion. 
These hypotheses will require a randomized control trial 
for confirmation.
In this review, an abnormal DRE is usually associated with 
significant elevations in the PSA probably due to late 
presentation. This significantly increases the sensitivity of 
PSA (99.2%). Sensitivity is the ability of a test to give a 
positive result for a condition when the person tested truly 
has that condition. It is a measure of the rate of positive 
results among diseased persons.[19] Specificity is the ability of 
a test to give a negative result when the person tested is truly 
free of the condition being tested for.[19] From this study, the 
decision to recommend treatment without needle biopsy is 
a matter of surgeon’s choice. This choice may be influenced 
by availability of trained pathologist and laboratory support. 
Despite the medicolegal implication of this method of 
treatment, the decision to proceed to treatment without 
needle biopsy may become pertinent under certain situations 
to improve patients’ quality of life.
Conclusion
The medicolegal implication of a missed diagnosis of PCa 
implies that all patients must have a PSA and a TRUS‑guided 
or finger‑guided needle biopsy before treatment. In places 
where trained pathologists are lacking or there is lack of an 
adequate laboratory support, DRE and PSA can guide the 
surgeon’s decision to proceed to treatment while awaiting 
confirmation of the diagnosis in cases where there is severe 
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